Pembrolizumab Receives Full Approval for Select Patients With MSI-H or dMMR Solid Tumors
March 29th 2023The FDA has granted full approval to pembrolizumab for the treatment of some patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors that have progressed following previous treatment.
Read More
The FDA wants to discourage the use of single-arm trials for accelerated approvals of oncology drugs; Cigna’s review system allows doctors to reject claims without reading them, an investigation shows; US bishops want to restrict gender transition care in Catholic hospitals.
Read More
Samyukta Mullangi, MD, MBA, oncology fellow at Memorial Sloan Kettering Cancer Center and incoming medical director at Thyme Care, discussed how the transition to value-based care can contribute to operational and financial risks among oncology practices, and the effectiveness of care navigation platforms in addressing these concerns.
Read More
Spending on novel therapies in high-risk bladder cancer had minimal impact on Oncology Care Model payments to practices, according to this cohort study and an average performance estimation.
Read More
Dr Manmeet Ahluwalia on Improving Genomic Testing Disparities in Oncology
March 12th 2023Manmeet Ahluwalia, MD, MBA, chief, Solid Tumor Medical Oncology; deputy director; and chief scientific officer at Miami Cancer Institute, addressed disparities in genomic testing among minority patients with cancer, as well as equitable care strategies at his organization’s Center for Equity in Cancer Care & Research.
Watch
Stops and Starts Abound in the Oncology Payment Landscape
March 10th 2023A session at the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit highlighted ongoing issues in oncology policy and payment, from the Cures 2.0 Act to 340B drug reimbursement.
Read More
Highlands Oncology Group’s Jeff Hunnicutt Discusses Risk Under the EOM
March 10th 2023Jeff Hunnicutt, CEO of Highlands Oncology Group, explains the 2 risk options provided under the Enhancing Oncology Model (EOM) and why the mandatory downside risk might give pause to practices that saw some success in the Oncology Care Model.
Watch
Dr Sigrun Hallmeyer Discusses Use of Precision Medicine in the First-line Setting
March 10th 2023As scientists are identifying molecular alterations in patients with later-stage cancers that may be targets in earlier-stage disease, next-generation sequencing is being utilized more in the first-line setting, noted Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.
Watch
Dr Kevin Davies: There Is Great Potential for CRISPR in Genetic Diseases and Cancers
March 9th 2023Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, discusses how CRISPR has evolved from the initial discovery of the double helix to now, with the technology holding great promise for both genetic diseases and cancers.
Watch
Multicancer Early Detection May Change the Screening Game—If We Learn From the Past
March 9th 2023A session at the ACCC 2023 Annual Meeting and Cancer Center Business Summit addressed the promise and potential drawbacks of multicancer early detection (MCED) testing for patients in the primary care setting.
Read More
Dr Andre Harvin: Pharmacists Play a Critical Role in Oncology Care
March 9th 2023Andre Harvin, PharmD, MS, MBA, Cone Health Cancer Center, discusses the vital role of pharmacists in oncology: how they use data to streamline patient visits, work to facilitate patient access to biosimilars, and advocate for their patients.
Watch
Samyukta Mullangi, MD, MBA, oncology fellow at Memorial Sloan Kettering Cancer Center and incoming medical director at Thyme Care, spoke on financial toxicity, heterogeneity of cancer, and other complex factors in oncology care systems that may perpetuate disparities in health care outcomes and delivery among patients.
Watch
Dr Olalekan Ajayi Previews the 2023 ACCC Annual Meeting
March 6th 2023Olalekan Ajayi, PharmD, MBA, chief operating officer of Highlands Oncology Group, PA, and 2023-2024 president-elect of the Association of Community Cancer Centers (ACCC), discusses why he is excited for this year’s meeting, including its many workshops and day 1 keynote on CRISPR.
Watch
Dr Stephen Schleicher: We’re at a Turning Point in Oncology Care
March 2nd 2023Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, discusses the present state of value-based oncology care and what the future may bring when the Enhancing Oncology Model kicks off on July 1.
Watch
Panel Addresses How Payers, Providers Can Optimally Use Real-World Evidence to Advance Cancer Care
February 23rd 2023Utilizing real-world evidence that applies to the specific care needs of certain patient populations can promote timely decision-making among payers and providers on the use of effective cancer therapies available on the market, said panelists at the 2022 Patient-Centered Oncology Care® (PCOC) meeting.
Read More